1 / 14

FDA Anesthetic & Life Support Drugs Advisory Comm. Sep.9, 2003

FDA Anesthetic & Life Support Drugs Advisory Comm. Sep.9, 2003. Art Van Zee, M.D. St. Charles Clinic St. Charles, Virginia . Overview: ---the OxyContin problem ---Opioids in the treatment of chronic non-malignant pain --Risks: ---diversion ---addiction --Benefits.

tailynn
Download Presentation

FDA Anesthetic & Life Support Drugs Advisory Comm. Sep.9, 2003

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. FDA Anesthetic & Life Support Drugs Advisory Comm. Sep.9, 2003 Art Van Zee, M.D. St. Charles Clinic St. Charles, Virginia

  2. Overview: ---the OxyContin problem ---Opioids in the treatment of chronic non-malignant pain --Risks: ---diversion ---addiction --Benefits

  3. Opioids in the treatment of chronic non-malignant pain RISKS: --Diversion --Addiction

  4. OxyContin Prescriptions Per Capita: Highest and Lowest States for 2000 IMS Health

  5. Opioids in the treatment of chronic non-malignant pain RISKS: --Addiction

  6. Addiction

  7. The risks of Addiction to opioids During treatment for chronic non-malignant pain: NOT KNOWN

  8. Opioids in the treatment of chronic non-malignant pain: The Benefits

  9. Conclusions: • Great harm from the OxyContin abuse problem • 2. High availability correlates with high abuse • 3. Many problems in a risk-benefit analysis of opioids in chronic non-malignant pain

More Related